Details of the Drug Combination

General Information of Drug Combination (ID: DCQET08)

Drug Combination Name
Cinacalcet Teriparatide
Indication
Disease Entry Status REF
Kidney Failure, Chronic Phase 1 [1]
Component Drugs Cinacalcet   DMCX0K3 Teriparatide   DMMC45B
Small molecular drug Peptide
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Cinacalcet
Disease Entry ICD 11 Status REF
Hyperparathyroidism 5A51 Approved [2]
Kidney disease GC2Z Phase 3 [2]
Cinacalcet Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Extracellular calcium-sensing receptor (CASR) TTBUYHA CASR_HUMAN Agonist [6]
------------------------------------------------------------------------------------
Cinacalcet Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [8]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Cinacalcet Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Decreases Activity [9]
Parathyroid hormone (PTH) OTD721UF PTHY_HUMAN Decreases Expression [10]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [11]
------------------------------------------------------------------------------------
Indication(s) of Teriparatide
Disease Entry ICD 11 Status REF
Exostosis N.A. Approved [3]
Myelofibrosis 2A20.2 Approved [3]
Osteogenesis imperfecta LD24.K0 Approved [4]
Osteoporosis FB83.0 Approved [3]
Psoriatic disorder EA90 Discontinued in Phase 2 [5]
Autosomal dominant hypocalcemia 5A50.0Y Investigative [3]
Teriparatide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Parathyroid hormone (PTH) TT6F7GZ PTHY_HUMAN Modulator [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02440581) Renal Osteodystrophy: An Individual Management Approach
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3308).
3 Teriparatide FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4448).
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030730)
6 Clinical pipeline report, company report or official report of Amgen (2009).
7 Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11.
8 Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
9 Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
10 Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. Am J Kidney Dis. 2006 Nov;48(5):832-7. doi: 10.1053/j.ajkd.2006.07.019.
11 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.